Please assess the completion status of the following clinical trial:

Trial Title: Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men in the age range from 18 to 60 years~* Full-night in-laboratory polysomnography with apnea-hypopnea index \> 30/h in the last three months~* Body mass index \< 35 kg/m2~* Informed consent~Exclusion Criteria:~* Already having started any treatment for sleep apnea, including use of continuous positive airway pressure~* NYHA heart failure, any class~* Predominantly central apnea~* Peripheral venous or lymphatic insufficiency~* Any chronic renal disease~* Use of diuretics and substances with action in the central or peripheral nervous system such as benzodiazepines, hypnotics, anticonvulsants, antidepressants, appetite suppressants, amphetamines, antiparkinson agents, muscle relaxants, bronchodilators~* Stroke within 6 months or with incapacitating sequelae~* Any physical, mental or social condition impairing the ability to participate in the trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lasilactone (Type: ACTIVE_COMPARATOR): Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
- placebo pill (Type: PLACEBO_COMPARATOR): One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
- Sodium-Restricted Diet (Type: ACTIVE_COMPARATOR): The diet group will receive a regimen with a prescribed intake of three grams of sodium per day

Based on this trial design, predict the completion outcome and termination type (if applicable).